Alkem Laboratories share price was down over 4 per cent after the pharmaceutical company said that it has received the inspection report from the United States health regulator of the company’s manufacturing facility situated at Ankleshwar, which comprises three 483 observations. Alkem Laboratories said in a statement that the USFDA - United States Food and Drug Administration had conducted an inspection at the company’s API - Active Pharmaceutical Ingredient manufacturing facility situated at Ankleshwar, India from 5th December to 9th December, 2016.
The company said that it shall put together a detailed response with adequate preventive and corrective measures to address the US FDA observations and the same is to be filed within the timeline stipulated by the US FDA. In the month of September, the USFDA had conducted an inspection at the firm’s manufacturing formulations facility situated at Daman from 20th September to 29th September, 2016, which received 13 observations. As per the USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health.
At 12:18 pm, Alkem Laboratories share price was down 4 per cent as compared to 0.48 per cent decline in the S&P BSE Sensex. A combined 104,542 shares changed hands on the counter on the NSE and BSE. The stock opened at Rs 1668.45.
According to Dynamic Levels analysts and researchers, Alkem Laboratories belongs to the top 500 shares set for this quarter. It is a good stock for investment and Dynamic Levels market analysts and experts expect good returns from it. The stock has both strong financials and fundamentals.
In order to know about the support and resistance levels of the scrip and also its fundamentals and financials, please a pay a visit to Alkem Laboratories share price history.
